The eye-watering profit projections of a new class of weight-loss drugs has become a focus of biotech and Big Pharma, with companies jockeying to bring new drugs to market and expand production capacity for those that already have approval.
Even as the initial rollout of drugs like Ozempic and Wegovy has just begun, there are already signs their potential is rippling through financial markets and long-term real estate plans. The stock prices of firms like Amgen and Eli Lilly are reacting in real-time to any news about the fate of their GLP-1 drugs, a class of synthetic peptides developed for diabetes that have been found…
Source: As Ozempic Slims Waistlines, It's Also Bulking Up Biomanufacturing Space